W STRATEGIES, LLC for ABBOTT LABORATORIES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R.4617: Protect Medical Innovation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
Education about the importance of proper reimbursement for home monitoring services for anticoagulation management. Education about the regulation of continuous glucose monitor technologies including CMS regulation of CGM.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Development of legislation regulated to regulation of LDT's, including a discussion draft of Diagnostic Accuracy and Improvement Act. Reauthorization of PAHPA (Pandemic All Hazards Preparedness Act). H.R.6: Support for Patients and Communities Act as it relates to provisions designed to promote the importance of non-pharmacological pain treatment options, including medical devices.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.